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Sinusoidal Vascular Disease: Review of Current Data
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Abstract
Idiopathic non-cirrhotic portal hypertension (INCPH) is a clinico-
pathologic disease entity characterized by the presence of clinical 
signs and symptoms of portal hypertension (PH) in the absence of 
liver cirrhosis or known risk factors accountable for PH. Multiple 
hematologic, immune-related, infectious, hereditary and metabolic 
risk factors have been associated with this disorder. Still, the exact 
etiopathogenesis is largely unknown. The recently proposed porto-
sinusoidal vascular disease (PSVD) scheme broadens the spectrum 
of the disease by also including patients without clinical PH who 
are found to have similar histopathologic findings on core liver 
biopsies. Three histomorphologic lesions have been identified as 
specific for PSVD to include obliterative portal venopathy, nodu-
lar regenerative hyperplasia and incomplete septal cirrhosis/fibro-
sis. However, these findings are often subtle, under-recognized and 
subjective with low interobserver agreement among pathologists. 
Additionally, the natural history of the subclinical forms of the 
disease remains unexplored. The clinical course is more favorable 
compared to cirrhosis patients, especially in the absence of clinical 
PH or liver dysfunction. There are no universally accepted guide-
lines in regard to diagnosis and treatment of INCPH/PSVD. Hence, 
this review emphasizes the need to raise awareness of this entity 
by highlighting its complex pathophysiology and clinicopathologic 
associations. Lastly, formulation of standardized diagnostic criteria 
with clinical validation is necessary to avoid misclassifying vas-
cular diseases of the liver and to develop and implement targeted 
therapeutic strategies.
Keywords: Liver; Cirrhosis; Nodular regenerative hyperplasia; In-
complete septal cirrhosis; Non-cirrhotic; Portal hypertension; Porto-
sinusoidal; Vascular injury
Introduction
Idiopathic non-cirrhotic portal hypertension (INCPH) is a clin-
icopathologic disease entity wherein the patient presents with 
portal hypertension (PH) without cirrhosis or underlying liver 
disease (chronic viral hepatitis, fatty liver disease, autoim-
mune hepatitis, hereditary hemochromatosis, primary biliary 
cholangitis, congenital hepatic fibrosis, sarcoidosis, schistoso-
miasis, etc.) that can cause PH [1]. Over the past decade, there 
has been a growing recognition among gastroenterologists, 
hepatologists and pathologists that the histologic findings of 
INCPH are not entirely specific to those with PH, and similar 
changes can be found in patients without PH. Thus, the novel 
entity “porto-sinusoidal vascular disease (PSVD)” has been 
introduced to broaden the definitional spectrum of INCPH 
and capture pre-PH phase of INCPH as well as INCPH that is 
concurrent with other liver diseases [2]. Yet, understanding the 
concept and clinical significance of PSVD, especially without 
PH, remains elusive.
In this review paper, we aim to systematically review the 
currently available evidence and enhance our understanding of 
INCPH and PSVD. More specifically, we provide an overview 
of the definition, terminologies and epidemiology of INCPH/
PSVD and review clinical, radiologic and histologic features 
of this rare entity, with emphasis on the evolving pathophysi-
ologic understandings that are currently available. This review 
would lay out a solid foundation for future studies of the natu-
ral history of PSVD in patients with no PH at the time of di-
agnosis.
Background
PH is defined by the presence of an elevated hepatic venous 
pressure gradient (HVPG, the difference between free hepatic 
venous pressure and wedge hepatic venous pressure) exceed-
ing 5 mm Hg. PH is often the result of increased resistance in 
the portal blood outflow tract [1]. Signs of PH include varices, 
porto-systemic collaterals, ascites and thrombocytopenia with 
splenomegaly (Table 1). Hepatic cirrhosis is the most common 
etiology of PH in the Western hemisphere while schistosomia-
sis is a frequent culprit in endemic areas to include southern 
and sub-Saharan Africa, South America, the Caribbean, parts 
of China and Southeast Asia [3-5]. The abnormal impedance 
to portal venous flow can occur at differing levels, such as the 
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prehepatic (i.e., portal vein), intrahepatic (involvement of in-
traparenchymal sinusoids and venules) or post-hepatic (i.e., 
hepatic veins) level. When signs and symptoms of PH develop 
in the absence of liver cirrhosis, the condition is designated as 
non-cirrhotic portal hypertension (NCPH).
Interestingly, some chronic hepatopathies that ultimately 
culminate in the development of cirrhosis can manifest as PH 
even before liver cirrhosis develops and qualify for NCPH al-
though admittingly, the terms NCPH and INCPH have been 
interchangeably used in the literature [5-7]. This includes alco-
holic and nonalcoholic fatty liver disease (NAFLD), metabolic 
liver diseases and autoimmune diseases such as primary bil-
iary cholangitis and primary sclerosing cholangitis. Exposure 
to medications and toxins, congenital hepatic fibrosis and infil-
trative liver diseases (i.e., sarcoidosis) can also be involved in 
the pathogenesis of PH without cirrhosis [1, 3, 5].
Yet, some patients present with PH without identifiable 
cause including the entities mentioned above. Only after ex-
cluding cirrhosis by histologic examination, eliminating a me-
chanical (i.e., portal vein thrombosis, Budd-Chiari syndrome 
(BCS)) or physiologic (i.e., right-sided heart failure) blood 
flow obstruction in the portal and hepatic venous systems 
clinically and/or radiologically, and confirming the absence of 
chronic liver disease or known risk factors for PH, can a diag-
nosis of INCPH be rendered [1].
INCPH vs. PSVD
INCPH encompasses a heterogenous group of hepatic dis-
orders for which the terminology was first introduced by 
Shouten et al in 2011 [1, 8]. Histologic features commonly 
seen in INCPH include obliterative portal venopathy (OPV), 
nodular regenerative hyperplasia and incomplete septal cirrho-
sis/fibrosis. Other findings include sinusoidal dilatation, mild 
perisinusoidal fibrosis, central vein abnormalities and variable 
portal vascular aberrancies (Table 2 [1, 2, 8-11]).
However, to date, this entity remains relatively poorly un-
derstood due to varying nomenclature and the lack of stand-
ardized diagnostic criteria. Furthermore, even though recent 
large-scale morphologic studies and collaborations on this top-
ic [9, 12-14] enabled us to have a better understanding of the 
pathogenesis of this entity and recognize the wide histologic 
spectrum it displays, several shortcomings still exist.
Firstly, histologic features of INCPH are not entirely spe-
cific as they can be seen in liver specimens from patients with-
out PH. Whether this finding represents a pre-PH phase of IN-
CPH is currently unknown and this notion remains somewhat 
speculative [12]. For example, portal vascular aberrancies that 
have been described in INCPH were seen in “normal” aging 
livers [15] and liver samples from trauma patients [16]. Simi-
larly, portal and lobular vascular changes that can be seen in 
INCPH were present in liver biopsies taken during gastric by-
pass surgery or cholecystectomy [13], in patients with hemo-
chromatosis with or without history of phlebotomy [14] and in 
nine (69%) of 13 patients on dialysis [17], all in the absence 
of PH. Likewise, in a recent interobserver variability study, 
the control group patients without PH who showed some fea-
tures of INCPH in their liver biopsies did not develop PH after 
a mean follow-up of 38 months [18]. In the absence of PH, 
these cases would not meet the diagnostic criteria for INCPH. 
Therefore, even if some of these indeed were to represent pre-
PH phase of INCPH, we will not be able to diagnose these 
patients as having INCPH at the time of liver biopsy. Secondly, 
it has been recognized that certain liver conditions that must 
be excluded to establish a diagnosis of INCPH (i.e., fatty liver 
disease, viral and autoimmune hepatitis, among others) may in 
fact coexist with INCPH [2]. In such cases, the restrictive defi-
nition of INCPH would exclude these patients from this group.
These conceptual limitations have led the Vascular Liver 
Disease Interest Group (VALDIG) to propose a novel entity de-
signed to broaden the whole aspects and spectrum of the disease 
in 2019. The term PSVD was introduced as the disease process 
primarily affects the hepatic sinusoids and portal venules [2].
However, this new classification is not without its own 
share of limitations. It might be too simplistic as it primar-
ily relies on histomorphologic features for diagnosis which 
are known to be subtle and often under-recognized. Moreover, 
while this classification attempts to broaden its spectrum, it 
also excludes certain conditions that may well co-exist with 
PSVD from the definitional spectrum.
Nomenclature
Previously, different terminologies have been used for INCPH/
PSVD. Idiopathic portal hypertension [19] and non-cirrhotic 
portal fibrosis [20] were commonly used in Eastern countries 
(Japan and India, respectively), while the terms “OPV” and 
“hepatoportal sclerosis” were endorsed in the Western litera-
ture [10]. Other terminologies that have been used for this en-
tity include “benign intrahepatic portal hypertension”, “intra-
hepatic noncirrhotic portal hypertension”, “noncirrhotic portal 
hypertension”, “idiopathic noncirrhotic intrahepatic portal 
hypertension”, “partial nodular transformation”, “incomplete 
septal cirrhosis” and “nodular regenerative hyperplasia” [1-3, 
6, 7, 10, 21]. Table 3 [3, 6, 12, 16, 19-68] summarizes the ter-
minologies used for this entity.
Table 1.  Symptoms and Signs of Portal Hypertension
Specific signs Non-specific signs
Clinical Variceal bleeding, collaterals seen on physical examination Ascites, thrombocytopenia, splenomegaly
Endoscopic Varices
Radiographic Porto-systemic collaterals, increased HVPG Ascites, splenomegaly
HPVG: hepatic venous pressure gradient.
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Definitions
In 2011, Shouten et al defined INCPH as a disease entity char-
acterized by the presence of PH in the absence of hepatic fi-
brosis/cirrhosis or other factors that may be accountable for the 
development of PH [1, 8]. As a result, chronic liver diseases, 
portal, splenic and splanchnic venous thrombosis, and BCS 
must be first excluded to render the diagnosis [1, 8].
On the other hand, the diagnosis of PSVD requires a core 
liver biopsy of sufficient length (≥ 20 mm or with ≥ 10 portal 
tracts) with no evidence of cirrhosis and with either a specific 
sign of PH (varices, PH related bleeding, porto-systemic col-
laterals on imaging) or a specific histologic lesion (i.e., OPV, 
incomplete septal fibrosis or incomplete septal cirrhosis, nod-
ular regenerative hyperplasia) for PSVD [2]. PSVD can also 
be diagnosed when not specific (of note, VALDIG used the 
particular term “not specific” in lieu of “nonspecific” in the 
manuscript) signs of PH (determined by VALDIG) and not 
specific histologic lesions of PSVD (determined by VALDIG) 
are present together, as long as a core ≥ 20 mm of non-cirrhotic 
liver is demonstrated [2]. As a result, in contrast to the INCPH 
scheme, neither the presence of a contributing factor for pa-
renchymal liver disease (i.e., metabolic, viral or alcoholic liver 
disease) nor the absence of clinical PH excludes the diagnosis 
of PSVD if a specific histologic lesion is present in a non-cir-
rhotic liver. Additionally, portal vein thrombosis (particularly 
when it is not accompanied by cavernoma) does not eliminate 
the possibility of PSVD as it was found to be commonly en-
countered along the natural course of the disease [2].
Nevertheless, some entities are not to be included in the 
broad definitional spectrum of PSVD and, when present, 
should prompt an alternative diagnosis. Infiltrative liver dis-
eases (i.e., sarcoidosis, malignancies), congenital hepatic fi-
brosis, schistosomiasis and heart failure must still be ruled out 
before diagnosing PSVD. Chronic cholestatic hepatopathies 
must also be excluded [2]. The following are conditions that 
closely resemble PSVD histologically and clinically, thus need 
to be excluded before rendering a PSVD diagnosis.
Alternative Diagnoses Excluded From PSVD 
Spectrum Despite Overlapping Histomorphology
BCS
BCS is characterized by the presence of hepatic venous out-
Table 2.  Histologic Features of Idiopathic Non-Cirrhotic Portal Hypertension/Porto-Sinusoidal Vascular Disease and Their Defini-
tions [1, 2, 8-11]
Specific features*
  Obliterative portal venopathy Wall thickening and fibrosis with luminal narrowing, obliteration and eventual loss of  
intrahepatic portal vein branches
  Nodular regenerative hyperplasia Micronodularity of hepatic parenchyma in the absence of liver fibrosis. Nodules are composed of 
hyperplastic central zones and peripheral atrophic hepatic cell plates.
  Incomplete septal fibrosis/cirrhosis Delicate fibrous septa originating from a portal tract and ending blindly within a hepatic lobule 
without clear connection to central veins or other portal tracts
Not specific features*
  Lobular changes
    Sinusoidal dilatation Sinusoidal lumen wider than one liver cell plate in the absence 
of artifactual tearing, usually non-zonal
    Megasinusoids Severe sinusoidal dilatation with cystic blood lake formation. Some authors 
used the term to describe dilated periportal shunting vessels.
    Perisinusoidal fibrosis Stellate pattern of collagen deposition around hepatic sinusoids highlighted by collagen stain
    Central vein abnormalities Central vein dilatation, pericentral vein fibrosis, multiplicity of central veins per lobule
  Portal tract changes
    Periportal shunting vessels Single or multiple thin-walled vascular channels seen outside but in contact with a portal tract
    Herniated portal vein Portal vein branch, often dilated, abutting the adjacent hepatic parenchyma 
at limiting plate without a rim of intervening connective tissue
    Portal tract remnant Portal tract smaller than twice the diameter of a bile duct, often with an inconspicuous/absent  
portal vein branch or herniated portal vein
    Increased arteriole profiles Arterialized portal venous branches with acquired smooth muscle layer
    Multiplicity of portal veins Increased number of portal vein branches within a portal tract, also known as angiomatous  
transformation
*Specific and not specific features (lesions) are determined by Vascular Liver Disease Interest Group. This categorization is applicable to porto-sinu-
soidal vascular disease only [2]. Specificity of these histologic lesions is unknown and not defined for idiopathic non-cirrhotic portal hypertension [11].
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flow tract obstruction (HVOTO) in the absence of right-sided 
heart failure or constrictive pericarditis [69, 70]. The terms 
BCS and HVOTO can be used interchangeably. BCS can be 
primary when the obstruction in the hepatic venous tract is the 
result of a thrombus in the context of a hypercoagulable state 
or secondary when it is related to invasion or encasement by 
a malignant tumor or an abscess [69]. The obstruction can oc-
cur at any level between small intrahepatic veins and the right 
atrium including the suprahepatic inferior vena cava.
BCS is usually identified by noninvasive imaging mo-
dalities such as Doppler ultrasound, triphasic multidetector 
computed tomography (CT) and magnetic resonance imaging 
(MRI) [70]. In typical cases, a liver biopsy is not required as 
histologic findings fail to show independent prognostic val-
ue when adjusted for the model for end-stage liver disease 
(MELD) or Child-Pugh scores [71]. Liver biopsy may be 
performed when the obstruction is at the level of intrahepatic 
small venules thus is not detected on imaging, or when the pa-
tient presents with cirrhosis of unknown etiology. The biopsy 
shows features of venous outflow obstruction pattern injury, 
which is a known histologic mimic of PSVD [72, 73] (Fig. 
1). Nevertheless, BCS/HVOTO is mainly a clinical/radiologic 
diagnosis and should not be considered a form of PSVD [2].
Sinusoidal obstruction syndrome (SOS)
SOS, previously known as a hepatic veno-occlusive disease 
Figure 1. (a) Liver biopsy from Budd-Chiari syndrome (BCS) shows 
venous outflow obstruction pattern injury with mild centrizonal sinusoi-
dal dilatation and congestion (hematoxylin and eosin (H&E), × 100). (b) 
Chronic BCS with extensive sinusoidal dilatation, centrizonal hepato-
cyte atrophy and dropout and fibrosis. The portal tracts are relatively 
spared (H&E, × 100).
Table 3.  Different Terminologies Used for Idiopathic Non-Cirrhotic Portal Hypertension/Porto-Sinusoidal Vascular Disease
Terminologies References
Idiopathic portal hypertension Kobayashi et al (1976) [19], Okuda et al (1982) [22], Nakanuma et al (1989) [23], Saito et al (1993) [24], 
Oikawa et al (1998) [25], Yamaguchi et al (1999) [26], Okudaira et al (2002) [27], Tsuneyama et al (2002) 
[28], Kogawa et al (2005) [29], Matsutani et al (2005) [30], Chang et al (2009) [31], Seijo et al (2012) [32], 
Furuichi et al (2013) [33], Siramolpiwat et al (2014) [34], Kotani et al (2015) [35]
Non-cirrhotic portal fibrosis Sarin et al (1987) [36], Mukta et al (2017) [20], Sood et al (2017) [37]
Obliterative portal venopathy Mikkelsen et al (1965) [38], Nayak et al (1969) [39], Cazals-Hatem et al (2011) [40], Glatard et al (2012) 
[41], Aggarwal et al (2013) [42], Franchi-Abella et al (2014) [43], Arora et al (2015) [44], Guido et al (2016) 
[12], Besmond et al (2018) [45]
Hepatoportal sclerosis Mikkelsen et al (1965) [38], Girard et al (2005) [46], Fiel et al (2007) [47], Krishnan et al (2012) [48]
Benign intrahepatic 
portal hypertension
Levison et al (1982) [49]
Intrahepatic non-cirrhotic 
portal hypertension
Kingham et al (1981) [50], Krasinskas et al (2005) [6], Eapen et al (2011) [51]
Non-cirrhotic portal 
hypertension
Ohbu et al (1994) [52], Nakanuma et al (1996) [16], Rajekar et al (2011) [3], Rajesh et al (2018) [53], Gioia 
et al (2018) [54], Nicoara-Farcau et al (2020) [55], Gioia et al (2020) [56]
Idiopathic non-cirrhotic 
intrahepatic portal hypertension
Hillaire et al (2002) [21], Goel et al (2011) [57]
Partial nodular transformation Sherlock et al (1966) [58], Wanless et al (1985) [59]
Nodular regenerative 
hyperplasia
Steinert et al (1959) [60], Wanless et al (1990) [61], Radomski et al (2000) [62], Austin et al 
(2004) [63], Malamut et al (2008) [64], Leung et al (2009) [65], Jharap et al (2015) [66]
Idiopathic presinusoidal 
portal hypertension
Polish et al (1962) [67]
Incomplete septal cirrhosis Sciot et al (1988) [68]
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(VOD), is regarded as a distinct entity that is not within the 
spectrum of PSVD. SOS is characterized by sinusoidal en-
dothelial cell damage due to exposure to exogenous toxins that 
result in partial or complete occlusion of small intrahepatic 
veins [74]. SOS/VOD often occurs as a fatal complication fol-
lowing hematopoietic stem cell transplantation (HSCT), but it 
can also be seen after exposure to certain chemotherapeutic/
immunomodulatory agents, in particular thiopurine deriva-
tives [74]. The Seattle and Baltimore diagnostic clinical cri-
teria have been extensively used in the setting of HSCT [75]. 
However, their applicability in non-HSCT patients is not well 
established, necessitating liver biopsy in some clinical settings 
[71, 73]. Common histologic findings include centrizonal con-
gestion and fibrosis involving sinusoids and/or central veins 
[73] (Fig. 2). Again, these histologic features fall within the 
spectrum of venous outflow obstruction pattern injury. Hence, 
liver diseases in patients with known history of bone marrow 
transplantation are excluded from the definition of PSVD [2].
Non-obstructive sinusoidal dilatation (NOSD)
NOSD has histomorphologic features that are overlapping with 
PSVD. NOSD is not universally defined; however, some au-
thors define NOSD as a finding of sinusoidal lumina that are 
wider than one liver cell plate and present in multiple lobules 
with no artifactual tearing, in the absence of post-sinusoidal out-
flow block (PSOB) [76, 77]. Its clinical significance is unclear 
but the sinusoidal widening should not be explained by infil-
tration by sickle cells, hemophagocytic histiocytes, neoplasms, 
BCS, heart failure or small-for-size syndrome after liver trans-
plantation, all of which feature PSOB. SOS/VOD should also 
be excluded even though NOSD can also be associated with 
drug exposures, notably oxaliplatin-based chemotherapy [77].
Peliosis
Peliosis is considered a severe form of sinusoidal dilatation 
with randomly distributed lobular cystic blood lakes [71]. Si-
nusoidal dilatation/peliosis are believed to be associated with 
an abnormal portal venous blood inflow or may represent a 
feature of severe systemic inflammatory reaction syndrome 
[77]. Peliosis, however, implicates a complete rupture of the 
reticulin framework which is not seen in NOSD [77]. PSVD 
may be part of the broader spectrum of sinusoidal dilatation/
peliosis [73].
Congenital porto-systemic shunt (CPS)
CPS represents an abnormal intra- or extrahepatic communica-
tion between intestinal/splenic venous blood and systemic cir-
culation bypassing liver parenchyma [78]. Extrahepatic CPS 
is referred to as Abernethy malformation and is excluded from 
the current definition of PSVD [2].
Epidemiology
It is difficult to estimate the incidence of INCPH/PSVD main-
ly due to varying/evolving nomenclature and geographic dif-
ferences regarding the identification and classification of this 
disorder. Notably, PSVD encompasses a larger population 
compared to INCPH as it also includes patients without clini-
cal PH. Moreover, PSVD was first introduced in 2019, thus the 
incidence of PSVD inclusive of those without PH is unknown.
INCPH has been widely recognized in Japan and the Indi-
an subcontinent over the past few decades where it constitutes 
approximately 30-40% of PH cases [10, 22, 79]. However, due 
to increased awareness of the disease and changes in national 
health policy, the incidence of INCPH has dramatically de-
creased in Japan to a total number of 11 new cases per year [2]. 
The high incidence of INCPH in India appears to be related to 
less favorable socio-economic conditions [20, 80]. In North 
America and Europe, INCPH is considered a rare disease as it 
accounts for around 3-5% of PH cases [10]. However, its inci-
dence is likely to be higher due to frequent under-recognition 
Figure 2. (a) Sinusoidal obstruction syndrome (SOS) associated with oxaliplatin chemotherapy. Marked centrizonal congestion 
and sinusoidal widening is noted (hematoxylin and eosin, × 100). (b) Trichrome stain shows perisinusoidal fibrosis (Masson-
trichrome, × 200).
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of this entity and the challenges inherent to the diagnosis and 
the interpretation of corresponding liver core biopsies. In fact, 
many INCPH patients might have been misdiagnosed as hav-
ing cryptogenic or autoimmune cirrhosis especially in cases 
without previous liver biopsy [6].
Geographic demographic differences are also noted. Pa-
tients affected with INCPH skew significantly younger in In-
dia and Japan (age ranges of 30 - 49 years and 40 - 59 years, 
respectively) when compared to Western countries (age range 
50 - 69 years) [2]. While the disease primarily affects women 
in Japan (although the gender gap is trending downward), it 
shows a male predilection in India, North America and Eu-
rope [2, 10]. INCPH has been rarely described in the pediatric 
population where it accounts for roughly 4.6% of all causes of 
PH [37]. In children, INCPH is more common in males and is 
more likely to be associated with an underlying malignancy or 
a genetic predisposition compared to adults [43, 45].
Pathophysiology and Etiologic Associations
The pathogenesis of INCPH/PSVD remains largely unknown 
but it is believed to be related to the injury to and occlu-
sion of the intrahepatic portal microvasculature leading to 
increased resistance to portal blood flow at the presinusoidal 
level [7, 79, 81]. In cirrhosis-related PH, the portal venous 
bed decreases but the hepatic arterial bed increases leading 
to various intrahepatic shunts [82, 83]. In INCPH/PSVD, on 
the other hand, both venous and arterial beds diminish in size 
and intrahepatic shunts seldom occur [25, 27]. The attenuated 
portal venous system along with subsequent phlebosclerosis 
results in increased blood pressure in non-stenotic venous 
branches [7]. The ensuing abnormal/aberrant intrahepatic 
portal vasculature in INCPH has been extensively studied 
and classified by Ohbu et al [52]. In this study, a combina-
tion of phlebosclerosis of portal venous branches and dilated 
periportal sinusoids that are not communicating with the por-
tal venous branches was commonly observed in INCPH and 
nodular regenerative hyperplasia. Phlebosclerosis of the por-
tal venous branches was less common in extrahepatic portal 
venous obstruction [52].
From a purely histomorphologic standpoint, the “por-
tal tract vasculopathy” scheme by Krazinskas et al brings an 
insight on the pathogenesis of INCPH/PSVD. The authors 
reported portal vascular abnormalities similar to the ones en-
countered in INCPH in 88% of native and allograft liver biop-
sies in the absence of PH and without significant differences 
between the two groups [7]. The authors proposed the term 
“portal tract vasculopathy” and suggested that portal inflam-
mation might be a potential etiologic factor. In the native liver 
group, portal tract vasculopathy was associated with hepatitis 
C virus (HCV) infection and increasing fibrosis whereas in the 
allograft group, it correlated with the severity of a synchro-
nous acute cellular rejection episode, the presence of previous 
rejection episodes and increased time following transplanta-
tion [7]. Similar portal changes were described in a Japanese 
HCV patient without PH or cirrhosis in a three-dimensional 
histologic reconstruction study [84]. These studies suggest that 
portal vascular changes that can be seen in INCPH/PSVD may 
be at least in part related to portal inflammation. However, IN-
CPH/PSVD biopsies usually do not demonstrate overt portal 
inflammation.
In addition, previous studies and reports have linked IN-
CPH/PSVD to various hematologic, immunologic, infectious 
and genetic disease processes [1, 3, 10]. Multiple factors may 
coexist and contribute to the pathophysiology of this disease.
Immune dysregulation
Multiple studies have reported an association between INCPH/
PSVD and disorders of immune function including congeni-
tal [85] (in particular common variable immunodeficiency 
(CVID)) and acquired immunodeficiencies (human immuno-
deficiency virus (HIV)-related) as well as autoimmune dis-
eases [2, 10]. For example, INCPH has been described in pa-
tients with inflammatory bowel diseases, rheumatoid arthritis, 
systemic lupus erythematosus, autoimmune hepatitis, sclero-
derma, Felty’s syndrome and celiac disease among others [10, 
24, 28, 29, 40, 63-65, 86]. Seropositivity for antinuclear, an-
timicrosomal and anti-DNA antibodies has also been reported 
[3, 23]. The underlying mechanism of immune-induced injury 
to the sinusoidal microvasculature is unclear but it appears to 
be related to hyperactivation of intrasinusoidal T lymphocytes 
[26, 35].
Hematologic factors
Prothrombotic conditions and hypercoagulable states are fre-
quently encountered in patients diagnosed with INCPH/PSVD 
[2, 10, 21, 34]. Some of the histologic features of INCPH, in 
particular OPV, may be related to previous or recurrent throm-
boembolic events [8]. Likewise, INCPH/PSVD is frequently 
complicated by portal vein thrombosis [2, 30, 31].
In fact, INCPH/PSVD and chronic portal vein thrombosis 
share common etiogenic grounds [87] and they display over-
lapping histologic features in liver biopsies [9]. Therefore, 
it would be very difficult or nearly impossible to distinguish 
these two, or determine whether portal vein thrombosis in IN-
CPH/PSVD represents an eventual end result of the disease or 
it develops de novo in a completely independent manner [73].
Infectious etiologies
INCPH/PSVD has been reported to correlate with recurrent 
intraabdominal infections especially in Eastern countries, al-
though this association remains inconclusive [1, 2]. HIV may 
also cause a direct virus-induced damage to the sinusoidal 
endothelial cells [88]. Endothelial cell injury may also occur 
as a result of prolonged exposure to antiretroviral treatment 
[31]. Additionally, HIV-related acquired protein S deficiency 
induces a state of hypercoagulability, a known risk factor for 
INCPH/PSVD [89]. Given the multitude of abnormalities seen 
in this population, the exact relationship between HIV and IN-
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CPH/PSVD appears to remain speculative [10].
Hereditary predispositions
Familial clusters of INCPH/PSVD have been reported, many 
of which were linked to a specific HLA haplotype (HLA-DR3) 
[36]. In familial cases, mutations in KCNN3 and DGUOK genes 
have been implicated. These alterations are transmitted in an 
autosomal dominant and recessive fashion, respectively [90, 
91]. Furthermore, those with certain congenital syndromes and 
hereditary diseases are at increased risk of developing INCPH/
PSVD (i.e., Turner syndrome, Adams-Oliver syndrome, phos-
phomannose isomerase deficiency, cystic fibrosis) [2, 46, 92, 
93]. Lastly, HIV patients who harbor specific single nucleotide 
polymorphisms (SNPs) in genes encoding the enzymes involved 
in purine metabolism are at increased risk of INCPH/PSVD 
when exposed to didanosine, an anti-retroviral agent [94].
Drug exposure
Exposure to variable drugs such as azathioprine, oxaliplatin, 
stavudine, didanosine and thioguanine has been linked to the 
development of INCPH/PSVD [2, 10].
Idiopathic
Some INCPH/PSVD patients present without any known risk 
factors. Cazals-Hatem et al reported that no risk factors of IN-
CPH were identified in 57% of patients with histologic OPV 
with or without PH at presentation [40].
Metabolic factors
Given the broadened definitional spectrum of PSVD, liver 
diseases that can cause pre-cirrhotic PH that are not included 
in the “to be excluded” conditions of PSVD would meet the 
diagnostic criteria of PSVD. The prime examples would be al-
coholic fatty liver disease and NAFLD.
There is growing evidence that PH can occur in alcoholic 
fatty liver disease and NAFLD even in the absence of signif-
icant fibrosis/cirrhosis and that it correlates with the degree 
of steatosis [95-101]. Although the exact etiopathogenesis 
remains unclear, multiple hypotheses have been proposed. 
Enlarged and ballooned fatty hepatocytes impair portal blood 
flow by narrowing the sinusoidal space. Consequent sinusoidal 
endothelial cell injury and loss of fenestrations facilitate en-
trapment of blood cells with increased deposition of extracel-
lular matrix in the space of Disse. Also, the endothelial cells’ 
inhibitory control on hepatic stellate cells diminishes leading 
to unrestrained vasoconstriction, further impeding the sinusoi-
dal blood flow. Resultant tissue hypoxia promotes inflamma-
tion, fibrosis and neovascularization by triggering Kupffer cell 
activation [95].
Animal studies have also shown that steatohepatitis in-
duces PH in the absence of fibrosis as a result of a hyperdy-
namic splanchnic circulation with increased portal blood flow 
and impaired arteriolar response to vasoconstrictors [97, 102]. 
Similarly, Mendes et al found that obesity and diabetes are in-
dependently associated with the development of PH [102]. In 
alcoholic liver disease, central sclerosing hyaline necrosis is 
believed to be the contributory factor to the development of 
pre-cirrhotic PH [101].
Likewise, Zuo et al found that individual morphologic IN-
CPH/PSVD lesions were significantly more common in stea-
totic liver specimens when compared to incidental biopsies, in 
the absence of PH [13]. This further corroborates the fact that 
fatty liver disease may contribute to the vascular remodeling 
seen in INCPH/PSVD though it will be difficult to determine 
which component is the main driver accountable for the histo-
logic changes (Fig. 3).
Etiopathogenic associations with PSVD are summarized 
in Figure 4.
Figure 3. (a) Fatty liver disease without cirrhosis or advanced fibrosis, but with portal hypertension. Zonal steatosis is noted 
(hematoxylin and eosin (H&E), × 40). (b) Higher magnification view showing pericentral fibrosis (long arrow) probably secondary 
to fatty liver disease, and phlebosclerosis (obliterative portal venopathy, short arrow), possibly secondary to concurrent porto-
sinusoidal vascular disease (H&E, × 100).
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Diagnosis
The diagnosis of INCPH/PSVD relies on a constellation of 
clinical, radiologic and histologic findings. Liver biopsy is in-
dispensable for documenting the absence of cirrhosis and as 
previously stated, can establish the diagnosis by itself when 
specific morphologic lesions of PSVD are identified [2].
Clinical presentation
Patients usually present with signs and symptoms of PH to in-
clude gastroesophageal (present in up to two-thirds of patients 
at the time of diagnosis) and anorectal varices, hypersplenism 
and thrombocytopenia [2, 80, 103]. Gastrointestinal bleeding 
secondary to ruptured varices is the most frequently encoun-
tered presenting symptom seen in up to 50% of patients [80]. 
There are 20-50% of patients presenting with ascites which of-
ten occurs in the setting of concurrent gastrointestinal infection 
or hemorrhage. Some patients, however, may be completely 
asymptomatic and signs of PH are discovered incidentally ei-
ther by radiologic or endoscopic means [34]. Less commonly, 
hepatic encephalopathy, hepatorenal and hepatopulmonary 
syndrome may develop [2, 80]. Hepatic synthetic function is 
relatively preserved, but progression to advanced hepatic in-
sufficiency requiring liver transplantation occurs in 4-19% of 
cases [40, 47, 104].
Subsequent portal vein thrombosis is frequently seen in 
INCPH/PSVD patients. In a study by Matsutani et al, nine 
(41%) of 22 patients with INCPH developed portal vein throm-
bosis after 12 years of follow-up, at a significantly higher in-
cidence compared to cirrhotic patients. Also, the development 
of portal vein thrombosis was an indicator of worse prognosis 
[30]. Similarly, portal vein thrombosis developed in 75% of 
INCPH patients with concurrent HIV infection after a median 
Figure 4. Etiopathogenic associations with porto-sinusoidal vascular disease. #Systemic lupus erythematosus, rheumatoid ar-
thritis, scleroderma, Sjogren’s syndrome, inflammatory bowel diseases, celiac disease, autoimmune hepatitis, Felty’s syndrome. 
¥Protein C or S deficiency, factor V Leiden, factor II mutation, antithrombin III deficiency. ±Antiphospholipid syndrome, malignan-
cy, ADAMTS 13 deficiency, oral contraceptive use. *Turner syndrome, Adams-Oliver syndrome, cystic fibrosis, phosphomannose 
isomerase deficiency. NAFLD: non-alcoholic fatty liver disease; HIV: human immunodeficiency virus.
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follow-up of 15 months [31].
As stated previously, clinical and or radiologic evidence 
of PH is not a prerequisite for the diagnosis of PSVD. As such, 
PSVD may be found during the workup of chronic abnormal 
liver function tests of unknown etiology. Elevated serum lev-
els of transaminases, alkaline phosphatase, gamma glutamyl 
transferase and bilirubin have been variably reported. Not 
uncommonly, patients may be referred to hematologists for 
thrombocytopenia secondary to hypersplenism or abnormal 
coagulation tests due to advanced liver dysfunction [79, 105]. 
However, PSVD may also be an incidental finding. For ex-
ample, in a study by Lee et al, histologic features of INCPH 
were identified in all liver biopsies from 13 dialysis patients 
but only a third (four of 13) had underlying PH, qualifying for 
INCPH [17]. Among the remaining nine patients without PH, 
six (66%) would have met the diagnostic criteria for PSVD 
given the presence of OPV in the liver specimens. Regardless, 
the authors speculated that the findings of histologic features 
of INCPH were reflective of the presence of known INCPH/
PSVD risk factors that are commonly encountered in this pa-
tient population. PSVD without PH was also reported as a 
form of vascular remodeling in regressed fibrosis following 
phlebotomy in hemochromatosis patients [14]. On the other 
hand, some PSVD patients without PH at presentation may de-
velop overt PH on follow-up studies [40, 79]. In Cazals-Hatem 
et al’s study, six (40%) of 15 patients with OPV in liver speci-
mens at presentation but without PH or portal vein thrombosis 
developed PH after a mean follow-up of 8.6 years [40].
Radiologic features
Imaging studies can be used to document the presence of PH 
either indirectly by noninvasive means (i.e., splenomegaly, 
porto-systemic collaterals) or directly by measuring the he-
patic venous pressures via catheterization of the hepatic veins. 
They can also identify disease processes that should be other-
wise excluded in order to diagnose PSVD (i.e., schistosomia-
sis, congenital hepatic fibrosis). Although radiologic findings 
often lack sufficient specificity to establish a diagnosis, there 
are some features that favor INCPH/PSVD.
First, combined hypertrophy of the caudate lobe and seg-
ment IV of the liver is suggestive of INCPH/PSVD whereas cir-
rhosis is usually associated with segment IV atrophy [41, 44]. 
Thickened hyperechoic walls of intrahepatic portal branches 
on ultrasound and increased periportal signal intensity on T2-
weighted MRI can be seen in some INCPH/PSVD patients and 
may represent periportal fibrosis [48, 53]. In addition, a nor-
mal or mildly elevated HVPG in the setting of overt stigmata 
of PH would support the diagnosis of INCPH/PSVD as it is 
indicative of a presinusoidal form of PH [32]. One caveat is 
that the presence of intrahepatic vein-to-vein communications, 
commonly seen in INCPH/PSVD, precludes an adequate as-
sessment of HVPG and subsequently would underestimate the 
actual value of the portal venous pressure [32, 106]. Also, it is 
important to note that even though preserved liver volume and 
the absence of nodular contours would favor INCPH/PSVD in 
the early stages of the disease [48], hepatic surface nodular-
ity resembling cirrhosis can be seen in INCPH/PSVD [10, 55] 
(Fig. 5). Abnormalities of the intrahepatic portal venous sys-
tem (i.e., reduced caliber, diminished visibility and occlusive 
thrombosis) are more commonly seen in INCPH/PSVD than 
in cirrhosis [41].
Data on liver stiffness measurement (via transient elas-
tography) are limited in INCPH/PSVD. However, recent stud-
ies have shown that it can be useful in distinguishing INCPH/
PSVD from cirrhosis [32, 33, 107]. INCPH/PSVD has signifi-
cantly lower mean liver stiffness compared to that of cirrhosis. 
In Elkrief et al’s study, the cutoff values of 10 and 20 kPa were 
found to have sufficient sensitivity and specificity, respective-
ly, in distinguishing the two [107]. For example, liver stiffness 
values lower than 10 kPa were highly suggestive of INCPH/
PSVD in patients with signs of PH whereas levels exceeding 
20 kPa effectively excluded the disease [107]. Additionally, 
hepatic venography shows frequent veno-venous shunts in IN-
CPH/PSVD with narrower angles between the large veins and 
their branches when compared to cirrhosis [108].
Histomorphologic findings
INCPH/PSVD lesions can be observed both in the portal tracts 
and within hepatic lobules. The definition of PSVD identifies 
three specific histologic lesions that are sufficient, per se, to 
establish the diagnosis even in the absence of clinical or radio-
logic features of PH: OPV, nodular regenerative hyperplasia 
and incomplete septal fibrosis/cirrhosis [2] (Table 2).
OPV, also known as phlebosclerosis [38], is considered 
to be the hallmark of PSVD. It is believed to be the initiating 
event leading to increased portal flow resistance and sustained 
presinusoidal hypertension [79]. OPV is characterized by mu-
ral fibrosis and thickening of intrahepatic small and medium-
sized portal vein branches with subsequent luminal narrowing, 
obliteration and venopenia [12, 42]. However, it is important 
to distinguish these features from portal dyads, a normal histo-
logic variant, where the lack of portal veins may be misinter-
preted as OPV [13].
Nodular regenerative hyperplasia was first introduced by 
Figure 5. Magnetic resonance imaging with contrast shows mild nodu-
lar contour of the liver surface (arrows) and relative hypertrophy of the 
caudate lobe (*) in porto-sinusoidal vascular disease.
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Steinert as a liver parenchymal micronodularity in the absence 
of fibrosis [60]. It appears to be the result of OPV with subse-
quent uneven perfusion of the liver parenchyma. The nodules 
are usually small (1 - 3 mm), ill-defined and composed of the 
hyperplastic central zones delineated by peripherally com-
pressed atrophic hepatic cell plates. The nodular architecture 
is better appreciated with a reticulin stain that highlights the 
condensed reticulin network at the periphery of the nodules 
[61, 79]. Cytokeratin 7 immunostain may also be helpful as it 
is often expressed in atrophic hepatocytes [109].
Incomplete septal fibrosis/cirrhosis is characterized by the 
presence of thin fibrous septae emanating from a portal tract 
and ending blindly within the hepatic lobule [79]. Although a 
vague and poorly demarcated hepatic nodularity can be seen, 
complete cirrhotic-type nodules should not be seen in incom-
plete septal fibrosis/cirrhosis (Fig. 6).
PSVD scheme defines not specific histologic lesions as 
those that can be associated with INCPH/PSVD but lack speci-
ficity. These include portal tract abnormalities such as aberrant 
vessels (i.e., periportal shunting vessels, herniated portal veins 
branches, multiplicity of portal vessels within a single portal 
tract, dilatation of arteries), irregular distribution of the portal 
tracts and central veins, non-zonal sinusoidal dilatation and 
mild perisinusoidal fibrosis [2] (Table 2). Additionally, portal 
tract remnants (defined as portal tract smaller than twice the 
size of a bile duct) are frequently seen in INCPH/PSVD [9, 
13, 14, 18, 79].
The most common lobular abnormality seen in INCPH/
PSVD is sinusoidal dilatation [1, 12, 40, 42, 79] as INCPH/
PSVD is a form of vascular pattern injury. However, sinusoi-
dal dilatation is not specific and can be associated with other 
vascular, neoplastic, inflammatory, infectious and medication-
related etiologies [77]. It is important to note that in INCPH/
PSVD, sinusoidal dilatation is random and non-zonal [2], 
whereas it is predominantly centrilobular when associated 
with usual etiogenic factors and mainly periportal when as-
sociated with oral contraceptive use [71]. Interestingly, a re-
cent reproducibility study on individual histologic features of 
INCPH/PSVD has shown that the recognition of sinusoidal 
dilatation was relatively reproducible amongst nine experi-
enced liver pathologists, although the zone in which sinusoidal 
dilatation was identified was not specified. This indicates that 
Figure 6. (a) Obliterative portal venopathy (also known as phlebosclerosis) with inconspicuous portal venous branch (arrow) 
(hematoxylin and eosin, × 200). (b) Incomplete septal fibrosis or cirrhosis (Masson-trichrome, × 150). (c) Nodular regenerative 
hyperplasia. The nodularity is highlighted by reticulin special stain (reticulin, × 30). (d) Trichrome stain shows the absence of cir-
rhosis in nodular regenerative hyperplasia (Masson-trichrome, × 30).
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recognizing sinusoidal dilatation may be a helpful clue in con-
sidering the diagnosis of INCPH/PSVD in the right clinical 
context [18] (Fig. 7).
In an attempt to standardize the variable terminologies 
used for these histologic lesions, specifically for INCPH, the 
International Liver Pathology Study Group proposed “portal 
vein stenosis” for phlebosclerosis and OPV, “herniated portal 
vein” for herniated portal vein branches, “hypervascularized 
portal tract” for multiplicity of portal vessels and “periportal 
abnormal vessels” for periportal shunting vessels [11].
Interobserver variability
Histologic lesions of INCPH/PSVD are heterogenous and fre-
quently overlap with other entities thus, display low interob-
server agreement even among experienced liver pathologists 
[18, 66, 110]. Liang et al recently have shown that the interob-
server agreement can be improved when OPV is recognized as 
the sole independent predictor of INCPH/PSVD. Further, the 
authors proposed three different categories for OPV: consistent 
with OPV, indeterminate for OPV and not consistent with OPV 
[110]. Whether this novel categorization improves diagnostic 
accuracy of INCPH/PSVD is yet to be determined and needs 
to be validated by future studies.
Inflow vs. outflow vascular abnormality
INCPH/PSVD is a presinusoidal form of PH thus falls within 
the spectrum of inflow vascular abnormality. Another cardinal 
example of inflow vascular abnormality with similar clinical 
and morphologic pictures is chronic non-cirrhotic, non-malig-
nant portal vein thrombosis [73]. Therefore, despite overlap-
ping clinical and morphologic features, INCPH/PSVD should 
be distinguished from hepatic venous outflow abnormality. 
Histologic hallmark of INCPH/PSVD is OPV in the portal 
tracts and other vascular and parenchymal changes are con-
sidered secondary to OPV [2]. In contrast, in outflow vascular 
abnormality (as in BCS, SOS and congestive hepatopathy), the 
morphologic changes predominate in the central zones (con-
gestion, necrosis and eventual fibrosis) and affect the central 
veins [73, 105]. Additionally, despite similar presenting symp-
toms, the clinicoradiologic context would be quite different 
between inflow and outflow abnormality. For example, the 
presence of heart failure in congestive hepatopathy, history of 
hematopoietic stem cell transplantation and drug exposure in 
SOS and radiologic evidence of hepatic venous outflow ob-
struction in BCS would essentially preclude the diagnosis of 
INCPH/PSVD. However, in a limited sample or advanced dis-
eases, determining primary lesion (portal tract vs. lobule) can 
be challenging.
Diagram summarizing the diagnostic approach for INCPH 
and PSVD is illustrated in Figure 8.
Management
There is no specific treatment for PSVD, especially in patients 
without PH as some of these patients may probably never de-
velop overt PH. In fact, the natural history of PSVD in the 
absence of PH is largely unknown [2] and large-scale prospec-
tive studies are needed in order to implement management rec-
ommendations in this patient population. Currently, the initial 
Figure 7. (a) Paraportal shunt vessel (arrow) in idiopathic non-cirrhotic portal hypertension/porto-sinusoidal vascular disease 
(INCPH/PSVD) (hematoxylin and eosin (H&E), × 200). (b) Irregularly distributed portal tracts and central veins in INCPH/PSVD. 
Non-zonal sinusoidal dilatation is also noted (H&E, × 50). (c) Mild perisinusoidal fibrosis (Masson-trichrome, × 130). (d) Rudimen-
tary portal tract in INCPH/PSVD (H&E, × 250).
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management for patients with INCPH and PSVD with PH is 
to identify and treat the underlying conditions known to be as-
sociated with the disease [10].
In INCPH, complications related to PH are managed in a 
similar fashion with those in patients with cirrhotic PH [10, 
80]. These patients should be screened regularly for gastroe-
sophageal varices and prophylactic measures for variceal 
bleeding should be implemented when varices are identified. 
Regarding the timing of endoscopic follow-up and the type of 
prophylaxis recommended in INCPH, the few studies availa-
ble failed to draw solid conclusions as only a small number of 
patients were studied [111, 112]. Therefore, in the absence of 
specific and universally implemented guidelines, the screen-
ing frequency and primary and secondary prophylaxis for var-
iceal bleeding in INCPH are similar to those recommended 
for cirrhotic PH. The prophylactic measures include the use of 
non-specific beta-adrenergic blockage and endoscopic band 
ligation [2, 56, 80, 113]. Similarly, the management for ascites 
and hepatic encephalopathy is identical to those in cirrhot-
ic patients. Transjugular intrahepatic porto-systemic shunt 
(TIPS) is reserved for patients with severe variceal bleeding 
and refractory ascites who fail conservative treatment. An 
international multicenter study showed that the outcomes of 
TIPS were favorable with a 2-year survival rate of 80% in 
INCPH patients [114].
Treatment with anticoagulants is often considered in IN-
CPH given the frequent association with portal vein throm-
bosis and underlying hypercoagulable state. However, routine 
use of anticoagulants in INCPH patients is currently not rec-
ommended due to insufficient evidence of benefit [113, 115]. 
On the other hand, current guidelines recommend biannual 
Doppler ultrasound in INCPH/PSVD patients for early detec-
tion of portal vein thrombosis [115]. Liver transplantation is a 
valid option for INCPH patients with advanced hepatocellular 
insufficiency. The data regarding outcomes after liver trans-
plantation in INCPH patients are limited, but appear overall 
favorable [6, 62].
Clinical Outcomes
In general, INCPH/PSVD patients fare considerably better 
than those with cirrhosis. Patients with INCPH/PSVD are less 
likely to develop ascites or hepatic encephalopathy than cir-
rhosis patients. Even though variceal bleeding is more com-
mon, the associated mortality is significantly lower compared 
to cirrhosis patients [34, 54]. This might be due to relatively 
preserved hepatocellular function in INCPH/PSVD [10].
Recent study has shown that the clinical course of PSVD 
without PH is more favorable than that of INCPH/PSVD with 
PH. Woran et al compared PSVD patients with PH (INCPH) 
to PSVD patients without PH and found the former to have 
higher Child-Pughes scores, higher prevalence of liver decom-
pensation and higher liver-related mortality compared to the 
latter [116].
Progression toward advanced hepatic failure and the de-
velopment of hepatocellular carcinoma are unusual in IN-
CPH/PSVD [104, 117, 118]. Hence, routine ultrasonographic 
screening for hepatocellular carcinoma is generally not recom-
mended in INCPH/PSVD patients [80].
Figure 8. Diagram summarizing the diagnostic approach for idiopathic non-cirrhotic portal hypertension and porto-sinusoidal 
vascular disease. *Portal vein thrombosis may be seen along the natural disease course of idiopathic non-cirrhotic portal hy-
pertension. #Biopsy adequacy criteria are available for porto-sinusoidal vascular disease (core liver biopsy ≥ 20 mm in length or 
featuring ≥ 10 portal tracts, or when considered adequate by an expert pathologist).
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Summary
In summary, INCPH/PSVD remains relatively under-recog-
nized and its incidence is probably underestimated. INCPH 
can be diagnosed when histologic features of INCPH/PSVD 
are identified in a non-cirrhotic liver biopsy from patients 
with PH of unknown etiology. Minimum histologic diagnostic 
criteria are not defined in INCPH. On the other hand, PSVD 
may be diagnosed in the absence of PH when aforementioned 
specific histologic features are present on liver biopsy. When 
not specific histologic features are only present, certain clini-
cal signs of PH are required to establish a diagnosis of PSVD. 
Future studies and investigations are needed in order to better 
define the significance of subclinical PSVD and to standardize 
diagnostic and therapeutic strategies. Although we acknowl-
edge that PSVD is a broader term, given the importance of 
PH in patients’ management, the term INCPH might be a bet-
ter choice than PSVD with PH. The term PSVD without PH 
would be a reasonable histologic diagnosis that can be used to 
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